Best of the Brokers for 17 December 2014

To appear in Best of the Brokers, email your research to

Jefferies reiterated its “buy” rating. The broker said the firm’s acquisition of PneumRx was “strategically sound, financially accretive and boosts top-line momentum”. It added that the deal offers “modest synergies” with BTG’s existing business, and boosted target price to 950p.

Cantor Fitzgerald reiterated its “buy” rating. The broker said that receiving regular payments for the firm’s exports remains a key focus for investors, and added that “a further payment expected before the new year, if achieved, will go some way to establishing a pattern of regularity”.